Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Analysis & Forecast: 2026-2033

Ornithine Transcarbamylase (OTC) Deficiency Treatment Market is estimated to be valued at USD 919.5 Mn in 2026 and is expected to reach USD 1,247.1 Mn in 2033, exhibiting a compound annual growth rate (CAGR) of 4.5% from 2026 to 2033. Increasing research and development activities for Ornithine Transcarbamylase (OTC) deficiency treatment by market players is expected to boost growth of the market over the forecast period. Moreover, increasing product approvals for Ornithine Transcarbamylase (OTC) deficiency treatment by regulatory bodies is expected to propel growth of the global Ornithine Transcarbamylase (OTC) deficiency treatment market over the forecast period

Analysts’ Views on Global Ornithine Transcarbamylase (OTC) deficiency treatment market:

For long-term management of ammonia in blood streams,gene therapy and nitrogen scavenger therapy are gaining popularity. Since, there are no U.S. FDA-approved drugs for OTC deficiency, companies in the Ornithine Transcarbamylase (OTC) deficiency treatment market should strengthen their R&D capabilities in order to innovate in IV medications. Key companies should innovate in the field of dietary supplements because daily protein and supplement intake will help to improve patient’s quality of life.

Figure 1. Global Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Share (%), by Drug Type, 2026

To learn more about this report, Download Free Sample

Global Ornithine Transcarbamylase (OTC) Deficiency Treatment Market - Driver

Increase in the research and development activities by market players  

Increasing research and development activities for Ornithine Transcarbamylase (OTC) deficiency treatment by market players is expected to drive the market growth over the forecast period. For instance, in April 2020, Arcturus Therapeutics, a clinical-stage messenger RNA medicine company, announced the acceptance of two clinical trials for its flagship asset ARCT-810, also known as LUNAR-OTC, a first-in-class mRNA therapeutic that is being developed to treat Ornithine Transcarbamylase (OTC) deficiency. The company’s Investigational New Drug (IND) application for Phase 1b study in patients with OTC deficiency was allowed to proceed by the U.S. Food and Drug Administration (FDA), and an additional Clinical Trial Application (CTA) for a Phase 1 study in healthy volunteers was approved by the New Zealand Medicines and Medical Devices Safety Authority (Medsafe).

Figure 2. Global Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Share (%), by Region, 2026

To learn more about this report, Download Free Sample

Global Ornithine Transcarbamylase (OTC) Deficiency Treatment Market- Regional Analysis

Among regions, North America is expected to dominate the market over the forecast period, owing to  North America’s 37.1% market share in 2026 and increasing product approvals for the treatment of Ornithine Transcarbamylase (OTC) deficiency, which is expected to drive the global Ornithine Transcarbamylase (OTC) deficiency treatment market growth in the region. For instance, in August 2022, iECURE, a gene editing company focused on developing therapies that utilizes mutation-agnostic in- vivo gene insertion, or knock-in, editing for the treatment of liver disorders with significant unmet need, announced that the U.S. Food and Drug Administration (FDA) had  granted Rare Pediatric Disease Designation to its lead product candidate, GTP-506, for the treatment of Ornithine Transcarbamylase (OTC) deficiency, a rare genetic condition that can lead to irreversible neurological impairment, seizures, coma, and death, in pediatric population.

Europe is expected to be second largest region in global Ornithine Transcarbamylase (OTC) deficiency treatment market over the forecast period  due to increasing research and development activities by key players in the region. For instance, in October 2021, Boehringer Ingelheim, a research-driven biopharmaceutical company, and Thoeris GmbH, a developer of therapeutic interventions intended for treating orphan diseases, announced a collaboration and license agreement with the aim to investigate novel first-in-class therapies for patients with urea cycle disorders (UCDs). UCDs are rare diseases caused by genetic liver dysfunctions, leading to excess ammonia levels in the blood and there is insufficient treatment available  for this disease till date.

As the link between regional warehouses was not smooth, transportation of raw materials between regions was not carried out successfully. This shortage of raw materials and components negatively affected the supply chain of the global Ornithine Transcarbamylase (OTC) deficiency treatment market.

This study revealed a negative impact on availability and access of essential drugs, sanitation, hygiene products, and antimicrobials. Most pharmaceutical companies and pharmacies in Namibia experienced delayed manufacturing and distribution of drugs,  and this attributed to reduced inter-country transportation of pharmaceutical goods and limited in-country capacity to manufacture drugs.

 Global Ornithine Transcarbamylase (OTC) Deficiency Treatment Market Segmentation:

 Global Ornithine Transcarbamylase (OTC) deficiency treatment market is segmented into Drug Type, Route of Administration, and Distribution Channel

Based on Drug Type, the market is segmented Buphenyl, Ravicti, Ammonul, and Others. Due to increased efficacy, drug cost, and improved patient compliance, Ravicti segment accounted for a significant share 36.2% in the global market in 2026.

In terms of Route  of Administration, the  global Ornithine Transcarbamylase (OTC) deficiency treatment market has been segmented into oral and intravenous. Due to patient preference for oral route and the convenience it provides, approvals and launches of oral medication, availability of a large number of products that can be administered through the oral route, and new products with improved formulation modification for taste masking, the oral segment is expected to dominate the market over the forecast period.

On the basis of Distribution Channel, market has been divided into hospital pharmacies, retail pharmacies, and online pharmacies. Due to the higher number of prescriptions filled at thehospital pharmacies,  favorable reimbursement scenario, strong supply chain management, and various patient assistance programme run by pharmaceutical companies, the hospital pharmacies segment expected to dominate the market over forecast period.

Global Ornithine Transcarbamylase (OTC) deficiency treatment market- Cross Sectional Analysis:

Among drug type, Ravicti segment expected to exhibit highest CAGR, in Asia Pacific region due to the key players in the market focusing on agreements for Ravicti in Asia Pacific. For instance, in May 2022, Immedica Pharma AB, a private European niche pharma group, and OrphanPacific, Inc., a Japan-based pharmaceutical company, announced that the companies have entered into an agreement, under which OrphanPacific gained the exclusive rights to Ravicti in Japan. Under the announced agreement, OrphanPacific is granted a license to develop, register, and commercialize the product in urea cycle disorders in Japan.

Among distribution channel, hospitals pharmacies segment is dominant in North America region due to growing hospital expenditure by governments, which is expected to provide strong growth prospects to the market during the forecast period. For instance, according to the U.S. Centers for Medicare and Medicaid Services 2021 findings on the National Health Expenditure (NHE) in the U.S., the hospital expenditure grew by 7.4% to reach US$ 1,270.1 billion in 2020, as compared to hospital expenditure in 2019. Additionally, prescription drug spending increased by 4.0% to reach US$ 348.4 billion in 2020, as compared to 2019.

Global Ornithine Transcarbamylase (OTC) Deficiency Treatment Market: Key Developments

Increasing number of initiatives for research and development activities for Ornithine Transcarbamylase (OTC) deficiency treatment market by market players is expected to propel the growth of the Global Ornithine Transcarbamylase (OTC) deficiency treatment market over the forecast period. For instance, in April 2021, Ultragenyx Pharmaceutical Inc., a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultra-rare diseases, announced the successful completion of End-of-Phase 2 (EOP2) meeting with the U.S. Food and Drug Administration (FDA), for the DTX301 Ornithine Transcarbamylase (OTC) deficiency gene therapy program. The meeting focused on the discussion of the Phase 1/2 data and alignment on Phase 3 design and endpoints. Based on the outcome of this meeting, Ultragenyx has finalized the Phase 3 study design, which will include a 64-week primary efficacy analysis period and enroll approximately 50 patients 12 years of age and older, randomized 1:1 to DTX301 (1.7 x 10^13 GC/kg dose) or placebo.

Global Ornithine Transcarbamylase (OTC) Deficiency Treatment Market: Restraint

High cost of Ornithine Transcarbamylase (OTC) Deficiency Treatment

Drugs such as RAVICTI are a nitrogen-binding agent that are approved for the treatment of chronic management of urea cycle disorder (UCD) in adults and children. RAVICTI is developed by Horizon Therapeutics and it costs around US$ 793,632 for a year of treatment of patient suffering from urea cycle disorder. RAVICTI is one of the most expensive drugs available in the U.S. for the treatment of Ornithine Transcarbamylase (OTC) deficiency. Government should focus on reimbursement policies for Ornithine Transcarbamylase (OTC) deficiency to boost the growth of the market.

Global Ornithine Transcarbamylase (OTC) Deficiency Treatment Market - Key Players

Major players operating in the global Ornithine Transcarbamylase (OTC) deficiency treatment market include Horizon Therapeutics Plc, Bausch Health Companies Inc, Danone, Nestlé, Ultragenyx Pharmaceutical., Arcturus Therapeutics, Inc., Abbott., Swedish Orphan Biovitrum AB, Acer Therapeutics Inc., Assertio Holdings, Inc., iECURE, and Translate Bio, Inc.